EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Saturday, June 15th 2019 at 11:00am UTC An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND …
Plus »Seres Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
Friday, June 14th 2019 at 1:23am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, today announced the pricing of an underwritten …
Plus »Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
Saturday, June 15th 2019 at 7:25am UTC 24-week results demonstrate significant improvement in repigmentation of facial vitiligo lesions after treatment with ruxolitinib cream Data presented at the World Congress of Dermatology support the planned initiation of a pivotal Phase 3 program, for which preparations are currently underway Investor conference call …
Plus »Servier annonce la décision de la Commission européenne de convertir l’autorisation conditionnelle de PIXUVRI® (pixantrone) en autorisation de mise sur le marché standard pour les patients atteints d’un lymphome non-hodgkinien agressif à cellules B
Thursday, June 13th 2019 at 3:32pm UTC Le pixantrone est disponible pour les patients depuis 2012 suite à une autorisation conditionnelle en Europe PARIS–(BUSINESS WIRE)– Servier a annoncé aujourd’hui que la Commission européenne (CE) a approuvé la conversion de l’autorisation conditionnelle de PIXUVRI® (pixantrone) en autorisation de mise sur le …
Plus »Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress
Friday, June 14th 2019 at 11:00am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate …
Plus »Flatiron Health Appoints Cancer Researcher and Pharmaceutical Executive Dr. Michael Vasconcelles as Chief Medical Officer
Friday, June 14th 2019 at 12:00pm UTC Former Unum Therapeutics, Takeda Executive to Advance Flatiron’s Work in the Development of Oncology Real-World Evidence NEW YORK–(BUSINESS WIRE)– Flatiron Health today announced that Dr. Michael Vasconcelles, a practicing oncologist and senior biotechnology and pharmaceutical executive, has joined as Chief Medical Officer, effective …
Plus »ArQule Announces Clinical Proof-of-Concept Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2019 EHA Annual Meeting
Friday, June 14th 2019 at 7:30am UTC -ARQ 531 demonstrates substantial anti-tumor activity and favorable safety profile -Four of six evaluable CLL patients, all with the BTK-C481S mutation, from cohort 7 (65 mg) experienced a Partial Response -Partial Response also observed in the study’s first Richter’s Transformation patient -Call with …
Plus »Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Friday, June 14th 2019 at 10:59am UTC In a descriptive analysis, addition of Empliciti to pomalidomide and dexamethasone reduced risk of death by 46% among patients with RRMM Empliciti-based combination showed improvements across efficacy endpoints, including continued progression-free survival benefit at 18 months PRINCETON, N.J.–(BUSINESS WIRE)– Bristol-Myers Squibb Company (NYSE: …
Plus »Servier anuncia la decisión de la Comisión Europea de convertir la aprobación condicional en una autorización de comercialización estándar para PIXUVRI® (pixantrona) en pacientes con linfoma no Hodgkin de linfocitos B agresivo
Thursday, June 13th 2019 at 2:30pm UTC Los pacientes pueden disponer de pixantrona desde 2012, tras una aprobación condicional en Europa PARÍS–(BUSINESS WIRE)– Servier ha anunciado hoy que la Comisión Europea (CE) ha aprobado la conversión de la aprobación condicional de PIXUVRI® (pixantrona) en una autorización de comercialización estándar como …
Plus »Debiopharm et Ipsen prolongent de 15 années leur partenariat stratégique pour le Decapeptyl® (triptoréline)
Wednesday, June 12th 2019 at 5:00am UTC Debiopharm et Ipsen prolongent et renforcent leur collaboration en cours afin d’assurer aux patients un accès au Decapeptyl® pour le traitement de certaines maladies urologiques, gynécologique et pédiatriques LAUSANNE, Suisse & PARIS–(BUSINESS WIRE)– Regulatory News : Debiopharm (www.debiopharm.com) et Ipsen (www.Ipsen.com) ont annoncé le …
Plus »
